Cancer detection
relying on the release of volatile biomarkers
has been extensively studied, but the individual biochemical processes
of the cells from which biogenic volatiles originate have not been
thoroughly elucidated to date. Inadequate determination of the metabolic
origin of the volatile biomarkers has limited the progress of the
scientific and practical applications of volatile biomarkers. To overcome
the current limitations, we developed a metabolism tracking approach
combining stable isotope labeling and flux analysis of volatiles to
trace the intracellular metabolism-derived volatiles and to reveal
their relation to cancer metabolic pathways. Specifically, after the 13C labeling of lung cancer cell, the isotopic ratio of whole
cellular carbon was measured by nanoscale secondary ion mass spectrometry-based
imaging. The kinetic modeling with the time-dependent isotopic ratio
determined the period during which cancer cells reach the metabolic
steady state, at which time all of the potential volatiles derived
from intracellular metabolism were fully enriched isotopically. By
measuring the isotopic enrichment of volatiles at the end-stage of
isotopic flux, we found that 2-pentadecanone appeared to be derived
from the metabolic cascade starting from glucose to fatty acid synthesis.
Furthermore, this biosynthetic pathway was determined to be distinct
in cancer, as it was upregulated in colon, breast, and pancreatic
cancer cells but not in normal cells. The investigation of the metabolic
footprint of 2-pentadecanone demonstrates that our novel approach
could be applied to trace the metabolic origin of biogenic volatile
organic compounds. This analytical strategy represents a potential
cutting-edge tool in elucidating the biochemical authenticity of cancer
volatiles and further expanding our understanding of the metabolic
network of airborne metabolites in vitro.